Skip to main content
. Author manuscript; available in PMC: 2021 Apr 1.
Published in final edited form as: Exp Neurol. 2020 Jan 16;326:113203. doi: 10.1016/j.expneurol.2020.113203

Figure 9:

Figure 9:

Effect of Nrf-2 and HO-1 inhibition on Mfsd2a-mediated BBB protection following SBI

Representative Western blot images (A) and quantitative analysis showing the expression of Mfsd2a (B), cav-1 (C), Keap-1 (D), Nrf-2 (E), HO-1 (F), occludin (G) and claudin-5 (H) at 24 hours following SBI. The overexpression of Mfsd2a was associated with significantly reduced expression of cav-1 and Keap-1 and significantly enhanced expression of Nrf2, HO-1 and TJP compared to non-treated injury groups following SBI. The administration of both Brusatol and ZnPP diminished the BBB protective effect of Mfsd2a and led to reduced expression of occludin and claudin-5 compared to Mfsd2a CRISPR Act group at 24 hours following SBI. Data are expressed as mean ± SD. n= 6/group. ANOVA, Tukey. **p<0.001 compared to Sham, *p<0.05 compared to Sham, ##p<0.001 compared to SBI, #p<0.05 compared to SBI, &&p<0.001 compared to SBI + Scramble CRISPR Act, &p<0.05 compared to SBI + Scramble CRISPR Act, $$p<0.001 compared to SBI + Mfsd2a CRISPR Act (2 μg), $p<0.05 compared to SBI + Mfsd2a CRISPR Act (2 μg), ^p<0.05 compared to SBI + Mfsd2a CRISPR Act (2 μg) + Brusatol.

SBI: Surgical brain injury

HHS Vulnerability Disclosure